

Belinda Hodson
fyi-request-3251-c924ac48@requests.fyi.org.nz

Ref: H201504894

Dear Ms Hodson

Response to your request for official information

I am writing in response to your Official Information Act request for

What are the full names of the research studies including clinical trials (both independent and drug company funded) that have been carried out on NZ patients to assess the safety and effectiveness of thyroid treatments e.g. Extended Release T3, Goldshield - for hypothyroidism, hyperthyroidism and thyroid cancer patients? All I require is the full APA references to these studies. If another organisation has done research, if you could name that organisation so I can contact them, that would be greatly appreciated.

which was due for response on 16 November 2015.

I apologize for the delay in providing a response to you, unfortunately an administrative error delayed our response.

The Secretariat of the Health and Disability Ethics Committees have made a provisional review of the recorded titles of ethics applications but we are unable to confirm if the studies located includes every study assessing the safety and efficacy of thyroid treatments for hypothyroidism, hyperthyroidism and thyroid cancer.

A manual check of all applications would be required to ensure we have located each study relating to your request, this would necessarily involve substantial collation and research. Accordingly, I would be required to refuse a more in-depth search of our records under Section 18(f) of the Act.


The studies itemized below are all that could be located in a provisional search of our electronic filing system under the search terms 'thyroid', 'Extended Release T3', and 'Goldshield'. The table below includes the HDEC reference number, the full study title, the name and organization of the co-ordinating investigator, and the sponsor if appropriate.

HDEC Reference	Title	Co-ordinating Investigator	Sponsor / Organisation
15/NTB/113	Utility of circulating microRNAs as a biomarker for differentiated thyroid cancer	Dr Goswin (Win) Meyer-Rochow	Department of General Surgery, Waikato Hospital
14/NTA/214	Protocol 20130356. A Randomised, Open - Label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCL in Paediatric subjects With Secondary hyperparathyroidism and Chronic Kidney disease Receiving Dialysis.	Dr Chanel Prestidge	Starship Children's Hospital
14/NTA/213	Protocol Number 20110100: An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis	Dr Chanel Prestidge	Starship Children's Hospital
14/CEN/81	A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis.	Dr Kannaiyan Rabindranath (Renal Department, Waikato Hospital)	Amgen Australia Pty Ltd
14/STH/39	Subclinical Congenital Hypothyroidism - Does It Have Long-term Effects?	Professor Paul Hofman	University of Auckland
13/NTB/133	Differentiated Thyroid Cancer Outcomes in the Auckland Region: A 5-Year Cohort 2003-2007	Dr James Johnston	NA
13/CEN/102	A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism	Dr Mark Marshall (CCRep, Middlemore Hospital)	Amgen Australia Pty Ltd
NTX/11/EXP/219	Study of Cricothyroid Ultrasound in Bariatric Anaesthesia (SCUBA Study)	Dr Gillian Mann	Auckland District Health Board

URB/06/04/0 23	Subclinical thyrotoxicosis in an outpatient population – Audit of clinical and biochemical outcome.	Dr Belinda Robb	Tairāwhiti District Health Board
NTX/11/EXP/ 142	Review of experience with thyroid surgery in Counties Manukau District Health Board (CMBD), and the relationship between thyroid disease and Vitamin D levels	Professor Randall Morton	Counties Manukau District Health Board
NTY/11/08/0 91	Comparison of Surgical and Medical therapy on the Natural History of Moderate to Severe Thyroid Eye Disease.	Dr Stephen Ng	Waikato District Health Board
NTY/12/02/0 18	Utility of circulating microRNAs as a biomarker for differentiated thyroid cancer	Dr Goswin Mayer-Rochow	Waikato District Health Board

I trust the information we have been able to provide fulfils your request. Please contact the Health and Disability Ethics Committee Secretariat by email (hdecs@moh.govt.nz) if you wish to make a more specific request for information.

Yours sincerely



Dr Don Mackie
Chief Medical Officer
Clinical Leadership, Protection & Regulation
Ministry of Health